Showing posts with label medical research. Show all posts
Showing posts with label medical research. Show all posts

Tuesday, August 24, 2010

Creating and characterizing communities of human gut microbes in gnotobiotic mice

Microbiology laboratories are laden with flasks, plates and freezers stocks containing axenic cultures and their products. In contrast, virtually every other habitat on Earth is filled with microbial communities of varying degrees of complexity. In this context, microorganisms are interdependent components of ecosystems; deciphering this dynamic requires a move from microbial organisms studied in isolation to model microbial communities studied under conditions that mimic those encountered by their members in their native habitats. Here, we focus on model communities consisting of microbes that inhabit the human body habitat containing our largest collection of organisms—the gut. The adult human gastrointestinal tract is a microbial bioreactor, containing all three domains of life. This ecosystem is teeming with microorganisms at its distal end (1011–1012 cells ml−1 luminal contents in the colon) and less so at its proximal end (an estimated 103–104 cells ml−1 luminal contents in the duodenum). The gut microbiota affects myriad aspects of our systems physiology, ranging from processing and harvesting of macronutrients and micronutrients (and xenobiotics!) from our diets, to shaping the features of our innate and adaptive immune system. Recently, deep sampling of the fecal microbial community has revealed that each of us harbor a collection of a several hundred bacterial phylotypes (Qin et al., 2010; Turnbaugh et al., 2010). The exact set of microbes differs from person to person although there is a greater degree of similarity between family members (Turnbaugh et al., 2009a, 2010). A catalog of several million genes present in the fecal microbiome has been assembled from analysis of a 577-Gbp data set obtained from shotgun sequencing of fecal community DNA prepared from 124 Europeans (Qin et al., 2010) and a 10.1-Gbp data set generated from a set of deeply sampled obese monozygotic co-twins living in the United States (Turnbaugh et al., 2010). These data sets provide a starting point for making in silico predictions about functions that can be attributed to the gut microbiota. Measurements of expressed mRNAs (Turnbaugh et al., 2010), proteins (Verberkmoes et al., 2009), and metabolites (Hoverstad et al., 1984; Li et al., 2008;Martin et al., 2008) in gut samples represent a first step toward testing these predictions.

Generating germ free mice via embryo transfer:-

Germ-free (GF) mice provide a complementary approach for characterizing the properties of the human gut microbiome. Methods for establishing and propagating inbred strains of mice under GF conditions were established >50 years ago by several groups. Re-derivation was based on caesarian section of a conventionally raised (microbe laden) mother, passaging the intact uterine horns containing the pups through a germicidal bath, and delivery of her pups in a GF isolator where they were suckled by a lactating foster mother (the original GF foster mothers were generated by caesarian delivery of litters, hand feeding of pups in an GF isolator with an autoclaved artificial liquid diet until a male and female reached reproductive maturity; colonies were established from these GF progenitors and their offspring distributed to other gnotobiotic facilities; for example seehttp://gordonlab.wustl.edu/SuppInfo/Reyniers_Sacksteder_1957.pdf). This approach requires precise timing and is also inefficient: in our experience, 0–5 wild-type pups survive to weaning age per re-derivation (n=100 C-sections performed between 1998 and 2007). Therefore, we have replaced this method with embryo transfer: embryos are harvested 1 day after mating, and transferred under sterile conditions to a pseudopregnant GF mother generated by mating to a vasectomized GF male. This technique yields 5–8 live born animals/25 embryos transferred/recipient mother (n>250 procedures). GF status is verified by PCR of feces using universal bacterial 16S rRNA gene primers and by culturing fecal and skin swabs under conditions that support growth of a broad range of anaerobic and aerobic bacterial species and fungi.

Studies of complex microbial communities  in gnotobiotic mice:-

GF mice can be colonized with microbial communities of varying complexity and origin at defined stages of their life. For example, gut microbial communities can be harvested from various body habitats of conventionally raised mice with defined genotypes and physiological phenotypes, and introduced into GF recipients (possessing a desired genotype) to determine how much of the donor phenotype is transferable to the resulting conventionalized mice via the microbiota. If complete or even partial phenotypic transfer occurs, follow-up studies can be performed to define composition of the donor community, the mechanisms by which the donor community impacts host physiology, and how the recipient affects the transplanted microbiota/microbiome. These types of studies have typically been performed using gut contents (Turnbaugh et al., 2006; Vijay-Kumar et al., 2010), but in principle can be extended to communities harvested from any body habitat.

We have developed procedures for subjecting GF and conventionalized mice to a variety of surgical and non-surgical manipulations while maintaining their gnotobiotic environments: these procedures include

(1) endurance training through swimming in a warmed sterile water tank placed within the isolator (a ‘gnotatorium’; Crawford et al., 2009); (2) using a plexiglass gnotobiotic transporter to bring mice to an irradiator for whole body irradiation; (3) bone marrow transplantation after whole body irradiation using marrow harvested from animals of varying genotypes (Crawford and Gordon, 2005); (4) using specialized transporters that fit inside a magnetic resonance imager to determine adiposity; and (5) techniques for generating aggregation chimeras using morula-stage embryos (for a discussion and illustration of why the stem cell hierarchy of intestinal crypts make chimeric mice such a powerful tool for studying cell autonomous versus non-autonomous regulation in the gut epithelium, see Wong et al., 2000).

We have also validated procedures for transplanting human fecal microbial communities into GF mouse recipients that are then fed diets that do or do not resemble those of the human donors (Turnbaugh et al., 2009b). We have found that a remarkable proportion of human fecal microbial diversity can be transferred in this manner even if the donor specimen had been frozen at −80 °C for 1–2 years (all bacterial phyla, up to 90% of class-level and genus-level taxa, and 60–90%of species level-phylotypes in donor samples are identifiable in recipient mice using 16S rRNA-based pyrosequencing). Once engrafted, the transplanted human microbial communities are remarkably stable, can be reliably transmitted across generations of animals, and exhibit well defined and reproducible biogeographical features along the length of the mouse gut (Turnbaugh et al., 2009b). Efficient intergenerational transfer of transplanted human fecal microbiota allows the microbiota and the host's innate/adaptive immune system to co-evolve beginning at birth in ‘second generation’ mice. ‘Humanized’ gnotobiotic mice can be used for proof-of-mechanism studies that cannot be readily conducted in humans where potentially confounding variables, including variations in host genotype, diet, and antibiotic consumption are notoriously difficult to control. A derivative of this procedure is to capture as much diversity as possible by culturing a donor's fecal microbiota, and then transferring this culture collectionen masse to wild-type or genetically engineered GF recipients (culturable ‘humanized’ mice).

Assembling defined model communities in vivo using gnotobiotic mice:-

As more members of the human gut microbiota are cultured and their genomes sequenced (Nelson et al., 2010), an opportunity exists to create model human gut communities in gnotobiotic mice where all community members and their complement of microbial genes are known. Members present in these synthetic human gut microbial communities can be selected from culture collections based on various criteria, including their consistent association with specific human physiologic or pathophysiologic states, their representation in a fecal microbiota that when transferred en masse confers a phenotype to recipient GF mice, their phylogenetic features, and/or by the results of in silico predictions of their functions based on inspection of their genomes. These communities can be used to address a number of basic questions in the field: for example (1) to what extent do priority effects, where established species are able to sequester limiting space or resources and are thereby able to exclude potential colonizers, determine community composition; (2) what is the strength of interspecific interactions (a key to generating predictive models of community structure and dynamics; Trosvik et al., 2010); (3) what are the genetic predictors of niche overlap; (4) how robust are the assembled communities to various environmental perturbations; and (5) what is the microbial host range of viruses and the determinants of viral lifecycles in various regions of the gut ecosystem (Reyes et al., 2010).

To date, these model communities have consisted of as few as 2 and as many as 15 members and have been used to explore some of the metabolic interactions that take place in the distal gut (both microbial–microbial and microbial–host; see Sonnenburg et al., 2006;Denou et al., 2009; Mahowald et al., 2009; Rey et al., 2010). These communities have also been extremely useful for technology development. For example, if the complete genome sequence of each member is known, then the relative abundance of each member can be used to infer the proportional representation of genes encoding various functions (for example metabolic and signaling pathways) in that community using quantitative metagenomic methods (Morgan et al., 2010). With the current capacity of the Illumina GAIIx DNA sequencer (~30 million reads per lane), relative and absolute species abundance is quantifiable for all microbes representing at least 0.01% of the community, while allowing greater than or equal to100 barcoded samples to be pooled in a single lane of the eight-lane flow cell for multiplex sequencing. These inexpensive assays of community member abundance support the large sample sizes needed for computational modeling of the responses of a defined (synthetic) community to various perturbations (including systematic alterations in macronutrient and micronutrient composition of the diet), across time.

Understanding how different gut communities modulate their gene expression in response to changes in diet, host physiological status, or invasion with microbial species is another key step in understanding the operations of the gut microbiota. RNA-Seq allows quantification of transcriptomes at high resolution and over a broad dynamic range. In the case of synthetic communities, where all the species and genes are known, this high-resolution data can be used to verify gene structure/operons, generate in silicoreconstructions of expressed metabolic pathways for each member in the community, and make predictions concerning the metabolic niches of each species. These predictions can be informed by RNA-Seq analysis of individual community members during monoculture under highly defined conditions (for example minimal medium supplemented with systematically varied carbon sources), then be validated using quantitative mass spectrometry-based analyses of products of microbial metabolism. These studies can prompt follow-up, hypothesis-based studies of metabolic niches where the investigator manipulates the species used to construct these model communities, or uses other approaches to perturb the activities of key members in ways that provide proof-of-principle tests for affecting community function and host physiology (for example devising ways to manipulate the hydrogen economy of the gut to affect the efficiency of fermentation and host energy extraction; Rey et al., 2010). In addition, gnotobiotic mice harboring defined collections of sequenced organisms provide an opportunity to further develop methods for extracting and characterizing, by LC-MS, the proteins expressed by their model microbiota (peptides can be readily mapped as all genes are known; Mahowald et al., 2009).

Community genetics provides another powerful technology to dissect the operations of microbial communities and to identify potential avenues (targets) for microbiome-directed therapeutics. Addition or removal of organisms before gavaging the model microbiota into GF mice provides the simplest genetic perturbation to identify species that confer a benefit or detriment to other community members or the host. Another method is insertion sequencing, which combines genome-wide transposon mutagenesis with massively parallel sequencing (Goodman et al., 2009). In this approach, complex populations of tens of thousands of transposon mutants of a given sequenced community member are generated and simultaneously introduced into wild-type or genetically manipulated GF mice in the presence or absence of other (sequenced) microbes. The representation of each mutant in the input community is determined by targeted, sequencing of transposon-adjacent chromosomal DNA, and compared with their representation in the output community recovered from the mouse. Differences in mutant representation in input versus output communities indicate which microbial genes confer a fitness advantage as a function of whatever selective pressure is intentionally applied to the system (Goodman et al., 2009).

Creating more realisitc defined microbial communities: the challenges ahead:-

A look to the near future reveals a number of pressing needs. With genome sequences available for almost 200 human gut isolates from eight bacterial phyla and Archaea, our ability to move toward larger model communities in gnotobiotic mice is limited by our ability to grow microbes in parallel; therefore, we need to identify media capable of supporting growth of diverse sets of microbes, scale-up methods for growing anaerobic cultures in parallel (for example move from tubes to 96-well plates or microfluidic chips with individually addressable strains), and modify sequencing pipelines to allow for rapid assays of purity of single cell-derived cultures. The current set of sequenced human gut bacteria isolates are largely from different individuals. Using microbial communities obtained from a single individual is desirable for reasons described above, including the fact that co-existing microbial species have co-evolved, creating distinct collections of strain-level phylotypes. Thus, to move toward increasingly realistic communities, we need high-throughput methods to isolate and array in multi-well plates, single cell-derived cultures of hundreds of bacteria from a single individual. Sequencing capacity will likely be available to many individual laboratories in the next few years to generate draft genomes from hundreds of these arrayed organisms. In the context of human microbiome projects, the ultimate informative model microbiota would contain microbes isolated from single individuals that confer the donor's phenotype to the recipient gnotobiotic mice. The full model community ‘tool kit,’ both experimental and computational (including application of existing and new methods for modeling) could be applied to these communities in an attempt to expedite understanding of how their component organisms and genes confer a donor phenotype. However, for these efforts to benefit and build the field, we also need to create the infrastructure necessary to readily share both communities and their associated data between laboratories. The knowledge base for model microbial community biology (conditions for culturing its members, microbial genome sequences, quantitative data about community membership as a function of various perturbations, associated meta-transcriptome, meta-proteome, and metabolomic data sets; information about their impact on host physiology) requires systems for data deposition, annotation, and retrieval, which combine computer automation and error checking with as little human curation as necessary. Finally, currently license agreements, biological safety regulations, and shipping procedures are designed to distribute individual strains or multiple variants of the same strain. We must streamline the regulatory and infrastructure hurdles for multi-species distribution to ensure that the best model communities developed over the coming years have the opportunity to earn their ‘model’ designation as they follow the path ofEscherichia coli and Bacillus subtilis as facilitators of biological discovery.

The ISME Journal (2010) 4, 1094–1098; doi:10.1038/ismej.2010.110; published online 22 July 2010

Monday, August 9, 2010

Merck Reports Encouraging Results for Hepatitis C Treatment

On Wednesday, Merck & Co. reported promising news about its experimental hepatitis C virus (HCV) treatment boceprevir, a protease inhibitor. In two late-stage clinical trials, patients taking boceprevir in addition to standard pegylated interferon and ribavirin had higher rates of sustained virological response than those taking standard therapy alone, Merck said. Sustained virological response (SVR) is defined as undetectable HCV 24 weeks after treatment ends.
The "Respond-2" study enrolled 403 patients who had previously failed HCV therapy and divided them into three groups: standard therapy plus boceprevir for 48 weeks; the same combination but treatment shortened to 36 weeks if HCV fell to certain levels; and those on standard therapy plus placebo.
SVR was achieved by 66 percent of patients in the boceprevir 48-week group, 59 percent in the short-term boceprevir group, and 21 percent taking the standard drugs with placebo.
The "Sprint-2" trial enrolled 1,097 patients with no prior treatment history. Though divided by similar groups, patients in the short-term arm could stop taking the boceprevir combination therapy after 28 weeks. SVR was achieved by 66 percent of patients in the 48-week arm, 63 percent of the short-term group, and 38 percent of the standard therapy group.
The results mean some HCV patients could shorten treatment by 12-20 weeks, said Peter Kim, president of Merck's research unit.
The most common side effects in the trials were fatigue, headache, and nausea.
Vertex Pharmaceuticals Inc. and Johnson & Johnson also are developing an HCV protease inhibitor, telaprevir, which had a 75 percent SVR rate among treatment-naïve patients. The firm has not yet announced late-stage data for treatment-experienced patients. Vertex could seek US approval of telaprevir this year. Boceprevir's SVR rate among previously untreated patients was 66 percent.
Merck plans to present its data in more detail at a medical conference in November, and anticipates submitting boceprevir for regulatory approval in the United States and Europe this year.

Wall Street Journal     (08.04.10):: Peter Loftus

Sunday, August 8, 2010

Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers

To identify susceptibility variants for hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), we conducted a genome-wide association study by genotyping 440,794 SNPs in 355 chronic HBV carriers with HCC and 360 chronic HBV carriers without HCC, all of Chinese ancestry. We identified one intronic SNP (rs17401966) in KIF1B on chromosome 1p36.22 that was highly associated with HBV-related HCC and confirmed this association in five additional independent samples, consisting of 1,962 individuals with HCC, 1,430 control subjects and 159 family trios. Across the six studies, the association with rs17401966 was highly statistically significant (joint odds ratio = 0.61, P = 1.7 × 10−18). In addition to KIF1B, the association region tagged two other plausible causative genes, UBE4B and PGD. Our findings provide evidence that the 1p36.22 locus confers susceptibility to HBV-related HCC, and suggest that KIF1B-, UBE4B- or PGD-related pathways might be involved in the pathogenesis of this malignancy.

Nature Genetics (2010) doi:10.1038/ng.01 August 2010

Saturday, August 7, 2010

Evasion of innate immunity by Mycobacterium tuberculosis: is death an exit strategy?

Samuel M. Behar, Maziar Divangahi & Heinz G. Remold

Abstract

Virulent Mycobacterium tuberculosis inhibits apoptosis and triggers necrosis of host macrophages to evade innate immunity and delay the initiation of adaptive immunity. By contrast, attenuated M. tuberculosis induces macrophage apoptosis, an innate defence mechanism that reduces bacterial viability. In this Opinion article, we describe how virulent M. tuberculosisblocks production of the eicosanoid lipid mediator prostaglandin E2 (PGE2). PGE2 production by infected macrophages prevents mitochondrial damage and initiates plasma membrane repair, two processes that are crucial for preventing necrosis and inducing apoptosis. Thus, M. tuberculosis-mediated modulation of eicosanoid production determines the death modality of the infected macrophage, which in turn has a substantial impact on the outcome of infection.

Nature Reviews Microbiology , | doi:10.1038/nrmicro2387

Wednesday, August 4, 2010

Antidote for leishmaniasis

New research has identified several organic compounds that could inhibit the growth ofLeishmania parasites, known to cause leishmaniasis in humans1. Guided by a computer-aided drug design system, the research has shown that the organic compounds block the activity of an enzyme that is key to the survival of these parasites in the host.

The study may help the development of drugs against leishmaniasis, which claims around 500,000 to 1 million lives every year across the globe. Existing therapies for leishmaniasis are toxic to humans and have also resulted in the emergence of drug-resistant parasitic strains.

The researchers studied a potential drug development target trypanothione reductase (TryR), an enzyme that helps the metabolic activities of the parasite for its survival in the host. TryR has ealier been successful in drug design studies on Trypanosoma cruzi, a parasite that causes Chagas disease.

The researchers chose to target TryR of Leishmania infantum and tested the inhibitory activities of three types of trycyclic organic compounds. They found that all the compounds bind to the active site of the enzyme through the formation of hydrogen bonds. The modelled binding modes provide an insight into the interactions of these compounds with the enzyme, and thus could be used for the design and synthesis of specific inhibitors.

"Because TryR is unique in the Leishmania parasite and is not found in the mammalian host, these TryR-targeted compounds may be exploited to yield safe, affordable drugs," says lead researcher Vikash Kumar Dubey.

  • References

    1. Kannan, S. et al. Molecular docking studies of selected tricyclic and quinone derivatives on trypanothione reductase of_Leishmania infantum_. J. Comput. Chem. 31, 2463–2475 (2010)

http://www.nature.com/nindia/2010/100728/full/nindia.2010.100.html

doi:10.1038/nindia.2010.100; Published online 28 July 2010

Wednesday, May 20, 2009

Healing the Heart with Bone-Marrow Cells

http://www.technologyreview.com/biomedicine/22676/?nlid=2042
A new treatment may help angina sufferers who are resistant to surgery and medication.
  • Injecting the hearts of angina sufferers with cells extracted from their own bone marrow can reverse the condition and relieve its symptoms, a new study suggests.
  • The Dutch cardiologists behind the placebo-controlled study say that the results may lead to radical new treatments for patients for whom surgery and medication bring little or no relief from this painful and debilitating condition, which results from narrowed arteries that cannot supply enough blood to the heart during exercise. All 50 subjects involved in the study were resistant to existing treatments.
  • Three months after being given the injections, patients' hearts were less starved of blood, and they were able to exercise more, researchers report in the latest issue of the Journal of the American Medical Association.
  • Lead researcher Douwe Atsma, a cardiologist at Leiden University Medical Center, in the Netherlands, hopes that follow-up studies, which are currently in progress, will also reveal lower death rates among those who received the treatment.
  • Atsma's team first fed catheters through patients' femoral veins, up into the aorta, and then into the heart's left ventricle--the chamber that pumps oxygen-rich blood back in the circulation. By touching an electro-sensitive tip around the chamber's surface, the researchers were able to locate areas of low electrical activity, where diminished blood supply had caused cells to die. They built up a "map" of the left ventricular surface of all 50 patients.
  • The researchers then took bone marrow from participants' hips and extracted the mass of mononuclear cells--an ill-defined mix of stem cells and progenitor cells.
  • In 25 of the patients, the researchers injected around 100,000 cells into angina-affected areas on the ventricular surface, using a modified form of the same catheter. The remaining 25 patients received a placebo injection of saline.
  • Three months after the treatment, more catheter tests showed that the average number of diseased grid areas in the hearts of treated patients had fallen from 4.2 to 1.8, or 57 percent. In patients given the placebo, the number fell from 3.8 to 3.1--a significantly smaller 18 percent reduction.
  • Bone-marrow recipients were also able to expend more energy on an exercise bike after three months: 114 kilocalories, compared with 107--a small but significant change. Placebo patients experienced an improvement of just 101 kilocalories compared with 99.
  • Earlier trials in which researchers sought to treat heart-attack victims with their own bone-marrow cells produced mixed results. Some studies found moderate improvements in a few measures of heart function, but none showed a clear health benefit.